文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-DOTATATE联合节拍卡培他滨治疗FDG阳性胃肠胰神经内分泌肿瘤

Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-02-18

这项前瞻性II期研究评估了177Lu-DOTATATE联合节拍卡培他滨作为放射增敏方案,在晚期进展性FDG阳性胃肠胰神经内分泌肿瘤(GEP-NET)患者中的疗效与毒性。37例G1-G3(Ki67<55%)患者接受5周期177Lu-DOTATATE(累计27.5 GBq)及inter-cycle口服卡培他滨(1000-1500 mg/日)。可评估的33例中,部分缓解10例(30%),疾病稳定18例(55%),疾病控制率85%;中位无进展生存期31.4个月,中位总生存期未达到;3-4级血液学毒性16.2%。结论认为该联合方案在侵袭性FDG阳性GEP-NET中有效且耐受良好。

要点

  • FDG阳性GEP-NET患者接受177Lu-DOTATATE联合节拍卡培他滨,疾病控制率达85%。
  • 中位无进展生存期为31.4个月,中位总生存期未达到。
  • 3-4级血液学毒性发生率为16.2%,未观察到肾毒性。

核心结论

  • 177Lu-DOTATATE联合节拍卡培他滨在侵袭性FDG阳性G1-G3 GEP-NET患者中具有活性且耐受良好。
  • 该数据为后续随机对照研究(PRRT单用 vs PRRT联合节拍卡培他滨)提供了依据。

研究设计与样本

  • 前瞻性II期研究,2015年8月至2016年12月连续入组37例晚期生长抑素受体和FDG双阳性G1-G3 GEP-NET患者(Ki67<55%)。
  • 治疗方案为177Lu-DOTATATE累计27.5 GBq,分5周期,每周期5.5 GBq,每8周一次;卡培他滨1000-1500 mg每日口服,在177Lu-DOTATATE治疗间期给药。
  • 所有患者在开始卡培他滨前接受二氢嘧啶脱氢酶(DPD)检测,仅DPD功能正常者入组。
  • 主要终点为疾病控制率(DCR)和安全性;次要终点包括无进展生存期(PFS)和总生存期(OS)。
  • 疗效按RECIST 1.1评估,毒性按CTCAE 4.0评估。

主要发现

  • 37例中,胰腺神经内分泌肿瘤25例(68%),胃肠神经内分泌肿瘤12例(32%);G1 12例(32%),G2 22例(59%),G3 3例(9%)。
  • 37例中33例可评估疗效:部分缓解10例(30%),疾病稳定18例(55%),疾病控制率85%。
  • 中位随访38个月(范围4.6-51.1个月),中位PFS为31.4个月(17.6-45.4),中位OS未达到。
  • 3-4级血液学毒性发生率为16.2%;其他3-4级不良事件为腹泻5.4%和乏力5.4%;随访期间未观察到肾毒性。

关键数值与推荐

  • 入组标准为晚期生长抑素受体和FDG双阳性G1-G3 GEP-NET,Ki67<55%,且DPD功能正常。
  • 177Lu-DOTATATE累计活性27.5 GBq,分5周期,每周期5.5 GBq,每8周一次。
  • 卡培他滨剂量为每日1000-1500 mg口服,在177Lu-DOTATATE治疗间期给药。
  • 疗效评估采用RECIST 1.1,毒性评估采用CTCAE 4.0。

临床怎么用

  • 对于FDG阳性、进展性G1-G3 GEP-NET患者,可考虑177Lu-DOTATATE联合节拍卡培他滨方案。
  • 开始卡培他滨前应进行DPD检测,仅DPD功能正常者适用。
  • 治疗期间需监测血液学毒性、腹泻和乏力,该方案未观察到肾毒性。

局限性

  • 本研究为单臂II期研究,样本量37例,无对照组。
  • 疗效可评估者仅33例。
  • 随访时间有限,中位OS未达到。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: FDG-positive neuroendocrine tumors (NETs) have a poorer prognosis and exhibit shorter response duration to peptide receptor radionuclide therapy (PRRT). The aim of this prospective phase II study was to evaluate the efficacy and toxicity of PRRT with 177Lu-DOTATATE associated with metronomic capecitabine as a radiosensitizer agent in patients with advanced progressive FDG-positive gastro-entero-pancreatic (GEP) NETs. PATIENTS AND METHODS: Patients with advanced somatostatin receptor- and FDG-positive G1-G3 GEP-NETs (Ki67 < 55%) were treated with a cumulative activity of 27.5 GBq of 177Lu-DOTATATE divided in five cycles of 5.5 GBq each every 8 weeks. Capecitabine (1000-1500 mg daily) was administered orally in the inter-cycle period between 177Lu-DOTATATE treatments. Prior to commencing capecitabine, all patients were triaged with the dihydropyrimidine dehydrogenase (DPD) test. Only DPD-proficient individuals were enrolled. The primary objectives were disease control rate (DCR) and safety. Secondary aims included progression-free (PFS) and overall survival (OS). Treatment response was assessed per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). Toxicity was assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. RESULTS: From August 2015 to December 2016, 37 subjects were consecutively enrolled. A total of 25 (68%) were affected by pancreatic neuroendocrine tumors (P-NETs), and 12 (32%) had gastrointestinal neuroendocrine tumors (GI-NETs). By grading (WHO 2010 classification), 12 patients (32%) had G1 (Ki67 ≤ 2%), 22 (59%) had G2 (3% < Ki67 ≤ 20%), and 3 patients (9%) had G3 (Ki67 > 20%) NETs. Grade 3 (G3) or 4 (G4) hematological toxicity occurred in 16.2% of patients. Other G3-G4 adverse events were diarrhea in 5.4% of cases and asthenia in 5.4%. No renal toxicity was observed for the duration of follow-up. In 37 patients, 33 were evaluable for response. Objective responses included partial response (PR) in 10 patients (30%) and stable disease (SD) in 18 patients (55%), with a DCR of 85%. The median follow-up was 38 months (range 4.6-51.1 months). The median PFS was 31.4 months (17.6-45.4), and mOS was not reached. CONCLUSIONS: This study demonstrated that the combination of PRRT with 177Lu-DOTATATE and metronomic capecitabine is active and well tolerated in patients with aggressive FDG-positive G1-G3 GEP-NETs. These data constitute the basis for a randomized study of PPRT alone vs. PRRT plus metronomic capecitabine.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Nicolini S, Bodei L, Bongiovanni A, et al. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2021. PMID: 33604690. doi:10.1007/s00259-021-05236-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。